Relevance of donor-specific antibody monitoring after kidney transplantation: Findings from the Collaborative Transplant Study and the Heidelberg Transplant Center.
Case-Control Studies
Complement C1q
/ metabolism
Graft Rejection
/ blood
HLA Antigens
/ immunology
Humans
Isoantibodies
/ analysis
Kidney Transplantation
/ adverse effects
Monitoring, Physiologic
/ methods
Predictive Value of Tests
Prognosis
Retrospective Studies
Tissue Donors
Transplantation Immunology
C1q
antibody-mediated rejection
donor-specific antibodies
graft rejection
graft survival
kidney transplantation
sCD30
tacrolimus
under-immunosuppression
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
27
06
2019
revised:
06
08
2019
accepted:
09
08
2019
pubmed:
14
8
2019
medline:
28
5
2020
entrez:
13
8
2019
Statut:
ppublish
Résumé
Monitoring of donor-specific HLA antibodies (DSA) has become part of the clinical routine in kidney transplantation. This paper gives a brief overview on data from the Collaborative Transplant Study (CTS) and the Heidelberg Transplant Center on the clinical relevance of post-transplant DSA monitoring in patients undergoing renal transplantation. The obtained findings underline the importance of DSA monitoring in the post-operative course in immunologically high-risk patients and patients with deterioration of graft function. Especially in patients with a pre-activated immune system, a gap in the immunosuppressive therapy appear to lead to persistence, reappearance or de novo occurrence of strong, complement-activating DSA, resulting in severe antibody-mediated rejection (AMR) and, without timely intervention, in AMR-related graft loss.
Substances chimiques
HLA Antigens
0
Isoantibodies
0
Complement C1q
80295-33-6
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-15Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157-1167.
Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant. 2009;9:1063-1071.
Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87:1505-1513.
Ozawa M, Terasaki PI, Castro R, et al. 14th International HLA and Immunogenetics workshop prospective chronic rejection project: A three-year follow-up analysis. In Clinical Transplants. Ch 26. Los Angeles, CA: Terasaki Research Institute; 2007:255-260.
Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95:19-47.
Wettstein D, Opelz G, Süsal C. HLA antibody screening in kidney transplantation: current guidelines. Langenbecks Arch Surg. 2014;399:415-420.
Süsal C, Wettstein D, Döhler B, et al. Association of kidney graft loss with de novo produced donor-specific and nondonor-specific HLA antibodies detected by single antigen testing. Transplantation. 2015;99:1976-1980.
Fichtner A, Süsal C, Höcker B, et al. Association of C1qfixing DSA with late graft failure in pediatric renal transplant recipients. Pediatr Nephrol. 2016;31:1157-1166.
Schaefer SM, Süsal C, Opelz G, et al. Pre-transplantsoluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients. HLA. 2016;87:89-99.
Gebel HM, Bray RA. A diagnostic 'C' saw: the ups and downs of C1q testing. Curr Opin Organ Transplant. 2019;24:402-410.
Süsal C, Döhler B, Ruhenstroth A, et al. Donor-specific antibodies require preactivated immune system to harm renal transplant. EBioMedicine. 2016;9:366-371.
Opelz G, Döhler B. Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation. 2008;86:371-376.
Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25:2757-2763.
Ro H, Min SI, Yang J, et al. Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation. Ther Drug Monit. 2012;34:680-685.
Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85:1404-1411.
Süsal C, Döhler B. Late intra-patient tacrolimus trough level variability as a major problem in kidney transplantation: a collaborative transplant study report. Am J Transplant. 2019. https://doi.org/10.1111/ajt.15346.
Rodrigo E, Segundo DS, Fernandez-Fresnedo G, et al. Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development. Transplantation. 2016;100:2479-2485.
Del Bello A, Congy-Jolivet N, Danjoux M, et al. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol. 2018;24:1795-1802.